To control the growing LSD and ASF epidemics in Europe and neighbouring countries by understanding the drivers of LSDV and ASFV emergence, and by generating research outputs which underpin novel diagnostic tools and vaccines, and authenticate appropriate and rapid responses by decision-makers.
“LSDV and ASFV are rapidly emerging high consequence diseases of livestock. Countries in grey/orange reported LSDV/ASFV prior to the start of this project in June 2018.”
African swine fever is a highly contagious disease of swine which causes a haemorrhagic death in up to 100% of pigs in a herd. In 2007 the virus was imported into the Caucasus, from where it has spread throughout eastern Europe. In 2018-19 the disease entered and spread throughout Asia, causing the deaths of millions of pigs and threatening the food security of the region.
Lumpy Skin Disease is a disease of cattle. It has been spread steadily north over the past 20 years from Africa through the Middle East and the eastern Mediterranean region. It entered Europe, the Balkans and Caucasus in 2014-16. The virus is an immediate and serious threat to cattle in Europe and eastern and central Asia.
Many of the European and neighbouring countries affected or threatened by ASF and/or LSD are represented on the DEFEND consortium.
DEFEND is a Horizon 2020 project running from 2018 to 2023. This research received funding from the European Union’s Horizon 2020 research and innovation programme under agreement No 773701.
The DEFEND consortium is led by Dr Pip Beard from The Pirbright Institute, UK.
|No.||Work Package Title||Lead Participant|
|1||Risk analysis framework||FLI|
|2||Phylogenetics of African swine fever virus and lumpy skin disease virus||Sciensano and The Pirbright Institute|
|3||Conflict, migration and virus spread||MPC and SIVtro VSF Italia|
|4||Transmission of lumpy skin disease virus||Sciensano|
|5||Subclinical infection with lumpy skin disease virus||Sciensano|
|6||African swine fever virus prevention and management||ISZLER|
|7||A novel African swine fever vaccine for use in interface regions||The Pirbright Institute|
|8||Diagnostic tools for lumpy skin disease||The Pirbright Institute and IDVet|
|9||Optimising lumpy skin disease vaccine strategies||ARC|
|10||Host determinants of lumpy skin disease resistance and susceptibility||SLU|
|11||Next generation lumpy skin disease vaccines||The Pirbright Institute and Zoetis|
|12||Communication and dissemination||The Pirbright Institute|
|13||Guaranteeing impact||The Pirbright Institute and Sciensano|
|14||Management||The Pirbright Institute|
|15||Ethics||The Pirbright Institute|